[Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
The efficacy of naftidrofuryl ( Dusodril ) for treatment of stage II arterial occlusive disease was evaluated in a controlled multi-centre study in a total of 104 out-patients with angiographically documented localization of occlusion. The therapeutic effect was assessed over three months by measurements of walking distance using standardized treadmill conditions. Further parameters were venoocclusive plethysmography and Doppler ultrasonography measurement of pressures. The complaint-free walking distance increased significantly during daily application of 600 mg naftidrofuryl orally (n = 54) during the 12-week assessment period when compared to the placebo group (n = 50). Taking the intraindividual variability of 17.2 m in assessment of walking distance into account, the increase of painless walking of 93 m after treatment for 12 weeks in the active-drug group is considered the result of treatment-induced increased performance.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005263:Femoral Artery; D005663:Furans / Q000008:administration & dosage*; D005684:Gait; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000008:administration & dosage*; D011897:Random Allocation; D013997:Time Factors
D005663:Furans; D009257:Nafronyl
Naftidrofuryl bei arterieller Verschlusskrankheit. Kontrollierte multizentrische Doppelblindstudie mit oraler Applikation.